ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: A randomized phase II study of the EORTC Brain Tumor Group.
EudraCT number 2014-004438-24
Protocol number M14-483
Sponsor AbbVie Deutschland, GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany
Indications Oncology
Diagnosis glioblastoma multiforme
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2015
Date of approval by Institute (SÚKL) 25.9.2015
Date of approval by EC 13.10.2015
Date of initiation CT in ČR 12.1.2016
Date of ending CT in ČR
Sites Fakultní nemocnice v Motole, Onkologicka klinika, V Úvalu 84, 150 06 Praha
Fakultní nemocnice Hradec Králové, Klinika onkologie a radioterapie, Sokolská 581, 500 05 Hradec Králové
Masarykův onkologický ústav, Žlutý kopec 7, 656 53 Brno
Fakultní nemocnice Ostrava, Onkologická klinika, 17. listopadu 1790, 708 52 Ostrava-Poruba

‹‹ Back to list